Co-Diagnostics files FDA 510(k) for flu and RSV point-of-care test

August 6, 2026 9:30 AM

Co-Diagnostics, Inc. (Nasdaq: CODX) announced it has submitted a Dual 510(k) premarket notification to the U.S. Food and Drug Administration ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found